OBJECTIVES:  Acute bacterial skin and skin structure infections (ABSSSI) are a frequent cause of morbidity for the community and represent the most frequent cause of admission to the emergency room. The aim of this study was to estimate the economic impact of dalbavancina in the treatment of hospitalized patients for ABSSSI from the perspective of the National Health Service (NHS). METHODS:  A Budget Impact excel based model was developed following the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) guidelines in order to estimate the costs of hospitalized patients with ABSSSI. The epidemiological and cost data for the standard of care (SoC) scenario were derived from an extrapolation of the national and regional administrative databases (hospital information system). All admissions for cellulitis, post-surgical infections and post-traumatic infections were selected in ordinary regime in terms of diagnosis related group (DRG) or International Classification of Diseases 9th revision as primary diagnosis. SoC scenario was compared to the innovative dalbavancina scenario where patients could reduce the length of stay to 4 days with an additional ambulatory admission at day 8 for subsequent administration RESULTS:  An average of 98.068 hospital admission per year for 954.663 hospital stay (9.7 days per admission) were extrapolated from the administrative databases. The model considers a mean annual costs in the SoC scenario equal to € 720.98 million. The introduction of dalbavancina within the therapeutic course of ABSSSI patient could generate a reduction of 5.7 days in terms of length of stay with a consequent cost reduction between € 75.71 and € 25.89 million depending on the scenario analysed (34% or 12% of total patients treated with dalbavancina respectively). CONCLUSIONS:  Adequate and effective administration of treatment is essential to shorten the hospital stay and in this context the introduction of dalbavancina could generate a significant reduction in spending on the National Health Service (NHS).